D.-A. Moutzouris

What's your call? ![Figure][1]</img> Computed tomography scan of the abdomen of an 87-year-old woman with 4-day history of fever, dysuria and left-flank pain. This patient had a history of renal colic and recurrent urinary tract infections. On physical examination she had tenderness at her

Living kidney donors represent a unique population of patients. Potential donors are selected based on the belief that their preoperative fitness is likely to mitigate the risks of long‐ and short‐term harm following uninephrectomy. Studies performed on postdonation outcomes have largely focused on mortality and the risk of end‐stage renal failure, but have also investigated secondary outcomes such as cardiovascular morbidity and hypertension. It has been postulated that hypertension is a possible outcome of living kidney donation. A variety of studies have been conducted to investigate the prevalence, epidemiology, mechanisms, treatment strategies, and long‐term ramifications of hypertension postdonation. These studies are heterogeneous in their population, design, methodology, and outcome measures and have presented contradicting outcomes. Additionally, the absence of a well‐matched control group has made it challenging to interpret and generalise the reported findings. As such, it is not possible to definitively conclude that hypertension occurs at a higher rate among donors than the general population. This article will review the evidence of postdonation hypertension prevalence, mechanisms, treatment, and complications.